Cumberland Pharmaceuticals Inc. (Cumberland) is specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Cumberland is focused on acquiring rights to, developing and commercializing prescription products for the hospital care and gastroenterology markets. Its product portfolio includes Acetadote (acetylcysteine) Injection, for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, for pain and fever, Kristalose (lactulose) for oral solution, a prescription laxative, and Hepatoren (ifetroban) Injection, for the treatment of patients suffering from hepatorenal syndrome (HRS). As of December 31, 2011, Hepatoren was in Phase II clinical development. In November 2011, the Company acquired the remaining rights associated with the Kristalose brand. During the year ended December 31, 2011, Cumberland acquired rights to a late-stage product candidate that it develops under the brand name Hepatoren.